PCRXPacira BioSciences, Inc.

$969M

Q4 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$95M+20.3% YoY

Gross Profit

$71M74.8% margin

Operating Income

$12M12.9% margin

Net Income

$8M8.7% margin

EPS (Diluted)

$0.20

QoQ Revenue Growth

+14.0%

Cash Flow

Operating Cash Flow

$21M

Free Cash Flow

$19M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$689M

Total Liabilities

$368M

Stockholders' Equity

$321M

Cash & Equivalents

$133M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$95M	$79M	+20.3%
Gross Profit	$71M	$58M	+23.1%
Operating Income	$12M	$8M	+44.9%
Net Income	$8M	$5M	+80.3%

Revenue Segments

EXPAREL

$94M100%

DepoCyt(e) and Other Products

$292,0000%

PCRX Q4 2018 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena